Author
Antonio D. De Lorenzo
Bio: Antonio D. De Lorenzo is an academic researcher. The author has contributed to research in topics: Bioelectrical impedance analysis & Lean body mass. The author has an hindex of 2, co-authored 2 publications receiving 3521 citations.
Papers
More filters
TL;DR: The use of bioelectrical impedance analysis (BIA) is widespread both in healthy subjects and patients, but suffers from a lack of standardized method and quality control procedures.
2,371 citations
TL;DR: Clinical use of BIA in subjects at extremes of BMI ranges or with abnormal hydration cannot be recommended for routine assessment of patients until further validation has proven for BIA algorithm to be accurate in such conditions.
1,759 citations
Cited by
More filters
TL;DR: Clinical use of BIA in subjects at extremes of BMI ranges or with abnormal hydration cannot be recommended for routine assessment of patients until further validation has proven for BIA algorithm to be accurate in such conditions.
1,759 citations
TL;DR: DXA-based analysis of fat and fat-free mass was performed in 50 cancer patients and compared with bioelectrical impedance analysis (BIA) and with regional computed tomography (CT) images available in the patients' medical records, finding CT presents great practical significance due to the prevalence of these images in patient diagnosis and follow-up.
Abstract: Human body composition is important in numerous cancer research domains. Our objective was to evaluate clinically accessible methods to achieve practical and precise measures of body composition in...
1,563 citations
Uppsala University1, University of Trieste2, University Hospital Southampton NHS Foundation Trust3, University of Oxford4, Winterthur Museum, Garden and Library5, University of Hohenheim6, University of Pennsylvania7, Universidade Federal de Minas Gerais8, Fujita Health University9, Aalborg University10, University of Vermont11, Mount Carmel Health12, Sapienza University of Rome13, Kristianstad University College14, Medical University of Vienna15, University of Nice Sophia Antipolis16, HAN University of Applied Sciences17, VU University Medical Center18, University of Erlangen-Nuremberg19, Peking Union Medical College20, Université libre de Bruxelles21, Rabin Medical Center22
TL;DR: An agreement of basic nutritional terminology to be used in clinical practice, research, and the ESPEN guideline developments has been established and may help to support future global consensus efforts and updates of classification systems such as the International Classification of Disease.
1,294 citations
TL;DR: The evolution, controversies and challenges in defining sarcopenic obesity are discussed, and current body composition modalities used to assess this condition are presented and current treatment strategies are outlined.
Abstract: The prevalence of obesity in combination with sarcopenia (the age-related loss of muscle mass and strength or physical function) is increasing in adults aged 65 years and older. A major subset of adults over the age of 65 is now classified as having sarcopenic obesity, a high-risk geriatric syndrome predominantly observed in an ageing population that is at risk of synergistic complications from both sarcopenia and obesity. This Review discusses pathways and mechanisms leading to muscle impairment in older adults with obesity. We explore sex-specific hormonal changes, inflammatory pathways and myocellular mechanisms leading to the development of sarcopenic obesity. We discuss the evolution, controversies and challenges in defining sarcopenic obesity and present current body composition modalities used to assess this condition. Epidemiological surveys form the basis of defining its prevalence and consequences beyond comorbidity and mortality. Current treatment strategies, and the evidence supporting them, are outlined, with a focus on calorie restriction, protein supplementation and aerobic and resistance exercises. We also describe weight loss-induced complications in patients with sarcopenic obesity that are relevant to clinical management. Finally, we review novel and potential future therapies including testosterone, selective androgen receptor modulators, myostatin inhibitors, ghrelin analogues, vitamin K and mesenchymal stem cell therapy.
756 citations
TL;DR: There is a need for improved assessment of adiposity in daily clinical practice, given the clear association between excess adiposity and adverse health consequences such as cardiovascular disease and type 2 diabetes mellitus.
Abstract: The prevalence of obesity in the United States and the world has risen to epidemic/pandemic proportions. This increase has occurred despite great efforts by healthcare providers and consumers alike to improve the health-related behaviors of the population and a tremendous push from the scientific community to better understand the pathophysiology of obesity. This epidemic is all the more concerning given the clear association between excess adiposity and adverse health consequences such as cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). The risks associated with overweight/obesity are primarily related to the deposition of adipose tissue, which leads to excess adiposity or body fatness. Furthermore, weight loss, specifically loss of body fat, is associated with improvement in obesity-related comorbidities. Before weight loss interventions can be recommended, however, patients must be assessed for their adiposity-related risk. Unfortunately, healthcare providers and systems have not done a good job of assessing for excess adiposity even in its simplest form, such as measuring body mass index (BMI). It is for these reasons that we must emphasize the importance of assessing adiposity in clinical practices. Although it can be argued that the entire population should be targeted as an important public health issue with a goal of prevention of weight gain and obesity, there are currently so many “at risk” individuals that simple strategies to identify and treat those individuals are necessary. We must identify those individuals at highest risk of comorbidities in order to identify those who might benefit the most from aggressive weight management.
This scientific statement will first briefly review the epidemiology of obesity and its related comorbidities, supporting the need for improved assessment of adiposity in daily clinical practice. This will be followed by a discussion of some of the challenges and issues associated with assessing adiposity and then by a review …
755 citations